@prefix this: <http://bio2rdf.org/drugbank:DB08905_nanopub.RAuLhWpmmNAqZy1zoJ35JQehnDo768OCo4FV-DXhyUDBA> .
@prefix sub: <http://bio2rdf.org/drugbank:DB08905_nanopub.RAuLhWpmmNAqZy1zoJ35JQehnDo768OCo4FV-DXhyUDBA#> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix dct: <http://purl.org/dc/terms/> .
@prefix pav: <http://purl.org/pav/> .
@prefix orcid: <http://orcid.org/> .
@prefix codebase: <https://github.com/tkuhn/bio2rdf2nanopub> .
@prefix version: <https://github.com/tkuhn/bio2rdf2nanopub/tree/eda7951a5f6c622c5d2132f50c3093138484a349> .
@prefix instance: <https://github.com/tkuhn/bio2rdf2nanopub#instance.MIIBtzCCASwGByqGSM44BAEwggEfAoGB> .
@prefix process: <https://github.com/tkuhn/bio2rdf2nanopub#instance.MIIBtzCCASwGByqGSM44BAEwggEfAoGB.7720f136-841b-4851-a6e4-ad20a409a475> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix v: <http://bio2rdf.org/bio2rdf_vocabulary:> .
@prefix d: <http://bio2rdf.org/drugbank:> .
@prefix dv: <http://bio2rdf.org/drugbank_vocabulary:> .
@prefix dr: <http://bio2rdf.org/drugbank_resource:> .
@prefix dcat: <http://www.w3.org/ns/dcat#> .
@prefix npx: <http://purl.org/nanopub/x/> .
sub:head {
   this: np:hasAssertion sub:assertion ;
    np:hasProvenance sub:provenance ;
    np:hasPublicationInfo sub:publicationInfo ;
    a np:Nanopublication .
}
sub:assertion {
   d:DB08905 v:identifier "DB08905" ;
    v:namespace "drugbank" ;
    v:uri "http://bio2rdf.org/drugbank:DB08905" ;
    v:x-identifiers.org <http://identifiers.org/drugbank/DB08905> ;
    dv:drugbank-id "DB08905" ;
    dv:x-atc <http://bio2rdf.org/atc:L02BG02> ;
    dv:x-cas <http://bio2rdf.org/cas:566-48-3> ;
    dv:x-kegg <http://bio2rdf.org/kegg:D07260> ;
    dv:x-wikipedia <http://bio2rdf.org/wikipedia:Formestane> ;
    dct:description """Formestane was the first selective, type I, steroidal aromatase inhibitor used in the treatment of estrogen-receptor positive breast cancer in post-menopausal women. Formestane suppresses estrogen production from anabolic steroids or prohormones. It also acts as a prohormone to 4-hydroxytestosterone, an active steroid which displays weak androgenic activity in addition to acting as a mild aromatase inhibitor. It is listed as a prohibited substance by the World Anti-Doping Agency for use in athletes. 

Formestane has poor oral bioavailability, and thus must be administered forthnightly (bi-weekly) by intramuscular injection. Some clinical data has suggested that the clinically recommended dose of 250mg was too low. With the discovery of newer, non-steroidal and steroidal, aromatase inhibitors which were orally active and less expensive than formestane, formestane lost popularity.

Currently, formestane (categorized as an anti-estrogenic agent) is prohibited from use in sports in accordance to the regulations of the World Anti-Doping Agency. It is not US FDA approved, and the intramuscular injection form of formestane (Lentaron) which was approved in Europe has been withdrawn."""@en ;
    dct:identifier "drugbank:DB08905" ;
    dct:title "Formestane"@en ;
    a dv:Drug ;
    rdfs:label "Formestane [drugbank:DB08905]"@en ;
    rdfs:seeAlso <http://www.drugbank.ca/drugs/DB08905> , <http://www.drugs.com/international/formestane.html> .
}
sub:provenance {
   sub:assertion prov:wasDerivedFrom <http://download.bio2rdf.org/release/3/drugbank/drugbank.nq.gz> .
  dr:bio2rdf.dataset.drugbank.R3 dcat:distribution <http://download.bio2rdf.org/release/3/drugbank/drugbank.nq.gz> .
  <http://download.bio2rdf.org/release/3/drugbank/drugbank.nq.gz> dct:created "2015-01-09T17:00:50-05:00"^^xsd:dateTime ;
    prov:wasDerivedFrom <http://www.drugbank.ca/system/downloads/current/drugbank.xml.zip#retrieved-on:2014-11-12T07:57:03-05:00> .
  <http://www.drugbank.ca/system/downloads/current/drugbank.xml.zip#retrieved-on:2014-11-12T07:57:03-05:00> pav:retrievedOn "2014-11-12T07:57:03-05:00"^^xsd:dateTime ;
    prov:wasDerivedFrom <http://www.drugbank.ca/system/downloads/current/drugbank.xml.zip> .
  <http://www.drugbank.ca/system/downloads/current/drugbank.xml.zip> prov:wasAttributedTo <http://drugbank.ca> .
}
sub:publicationInfo {
   sub:signature.MCwCFAoZZKYmWrqP npx:hasPublicKey "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" ;
    npx:hasSignature "MCwCFAoZZKYmWrqPQOFSysz2v0xqWxbfAhRLYD5aqv62Qrc1dPO/t3WSgLrUbQ==" ;
    npx:signedBy instance: .
  this: dct:created "2018-03-30T11:11:11.534+02:00"^^xsd:dateTime ;
    dct:license <https://creativecommons.org/licenses/by-nc/4.0/> ;
    npx:hasSignatureElement sub:signature.MCwCFAoZZKYmWrqP ;
    prov:wasGeneratedBy process: .
  instance: prov:specializationOf codebase: ;
    prov:wasAttributedTo orcid:0000-0002-1267-0234 .
  process: dct:identifier "7720f136-841b-4851-a6e4-ad20a409a475" ;
    prov:used version: ;
    prov:wasAssociatedWith instance: ;
    prov:wasStartedBy orcid:0000-0002-1267-0234 .
  version: dct:isVersionOf codebase: ;
    pav:version "eda7951a5f6c622c5d2132f50c3093138484a349" ;
    prov:wasAttributedTo orcid:0000-0002-1267-0234 .
}